Ken Griffin Immuno Gen, Inc. Put Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2023 Feb 14, 2024	BUY	$12.46 - $29.95 $270,382 - $649,915	21,700 Added 8.14%	288,200 $8.55 Million
Q3 2023 Nov 14, 2023	BUY	$14.09 - $19.87 $598,825 - $844,475	42,500 Added 18.97%	266,500 $4.23 Million
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $213,375 - $1.14 Million	56,900 Added 34.05%	224,000 $4.23 Million
Q1 2023 May 15, 2023	BUY	$3.67 - $4.92 $465,356 - $623,856	126,800 Added 314.64%	167,100 $641,000
Q4 2022 Feb 14, 2023	BUY	$4.55 - $6.31 $113,750 - $157,750	25,000 Added 163.4%	40,300 $199,000
Q3 2022 Nov 14, 2022	SELL	$4.48 - $6.47 $29,568 - $42,702	-6,600 Reduced 30.14%	15,300 $73,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.